Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume. by Gregory, W. M. et al.
Br. J. Cancer (1990), 62, 671-675
1990
Using mathematical models to estimate drug resistance and treatment
efficacy via CT scan measurements of tumour volume
W.M. Gregory', R.H. Reznek2, M. Hallett2 & M.L. Slevin2
'Medical Oncology Unit, Guy's Hospital, St Thomas's Street, London SE] 9RT; and2Departments ofRadiology and Medical
Oncology, St Bartholomew's Hospital, London ECIA 7BE, UK.
Summary A previously described mathematical model designed to evaluate resistance and tumour-kill for
individual patients, and to predict changing tumour sizes, has been applied to patients with small cell lung
cancer. The model requires tumour volume measurements, and these were obtained via computed tomography
scans of the chest. The model fitted the data well, and was able to predict later tumour volumes using earlier
ones, as well as suggesting times at which to change or abandon treatment for individual patients. The model
gave estimates for resistance and tumour-kill which may provide additional useful outcome measures for
clinical trials, and help in the design of future studies.
The standard measures of success in clinical trials, namely
differences in response rates, response duration or survival,
although essential, yield little information as to why a partic-
ular regime fares better, or by what means prognosis is
improved. Consequently the rationale for proceeding from
one trial to the next is often unclear, many trials are needed
to establish the principles on which development may take
place, and trials often seem to produce contradictory results
(Slevin & Staquet, 1986).
Attempts have been made, in recent years, to explain and
interpret results from clinical trials in terms of resistance to
and efficacy of chemotherapy, and differences in tumour
growth rates using mathematical models (Birkhead &
Gregory, 1984; Birkhead et al., 1986; Goldie & Coldman,
1979; Skipper & Perry 1970). Such models, it is hoped, will
provide meaningful explanations for trial differences, improv-
ing the speed and direction of research.
The models of Goldie & Coldman (1979) and Skipper &
Perry (1970) espouse general principles, such as the alter-
nating of non-cross-resistant drug combinations. A model
has also been developed for individual patients (Birkhead &
Gregory, 1984; Birkhead et al., 1986). It was thought that,
once validated, such a model might enable results to be
achieved on smaller numbers of patients, since the additional
interpretative information ought to improve the power of any
tests used. An attempt is made to validate this model on
patients with small cell lung cancer (SCLC). The model
requires an accurate method of measuring tumour volumes,
and computerised tomography (CT) scans of the chest have
been employed to this end. Having estimated the resistance
to and efficacy of chemotherapy, and the tumour growth
rate, the model predicts the sequence of tumour volumes
before each course of chemotherapy. The validity and
accuracy of these predictions were tested on a series of up to
seven scans on each of nine patients with SCLC.
DIAGRAMMATIC REPRESENTATION OF THE MODEL
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Figure I Diagrammatic representation of the model.
supply and the likely stochastic nature of cell-killing by
cytotoxic agents. The tumour growth rate is empirically
assumed to be exponential for the period of therapy, and it is
assumed that throughout the treatment period the mutation
rate from sensitivity to resistance or vice versa is negligible in
comparison to the other effects.
The proportion of sensitive tumour killed by each cycle of
the treatment is assumed to be the same (Skipper & Perry,
1970), and is represented by k. The proportion of tumour
initially resistant is represented by R. The tumour doubling
time is denoted by d. The model predicts, for particular
values of these three independent variables, k, Ro and d,
given the above assumptions, the sequence of tumour
volumes before each treatment cycle (Birkhead & Gregory,
1984), as shown in the Appendix.
The model
The model seeks to relate changing tumour volumes to pro-
portions of sensitive and resistant tumour, and to tumour
growth rate. This is represented diagrammatically in Figure
1. Resistant tumour is assumed to be tumour which can
never be killed with the given drug dose due to inherent
(cellular) resistance. The remaining tumour is considered sen-
sitive, although not all of it will be killed by a single
administration of the drug, due to such factors as cells not
being in cycle, uneven drug distribution, problems of blood
Patients and methods
Patients
Nine patients with SCLC had tumour volumes measured.
They were taken from two separate trials, one comparing
etoposide and adriamycin (VA) with oncovin, etoposide and
adriamycin (OVA) in limited disease patients, the other com-
paring two different schedules of etoposide given as a single
agent in extensive disease (Slevin et al., 1989), the same dose
of etoposide being given as a continuous infusion for 1 day,
or as separate 2 h continuous infusions over 5 days.
The observed tumour volumes along with the times (in
days) since the start of treatment, at which the scans were
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taken, are given in Table I, and shown diagrammatically in
Figures 2 and 3. Patients with peripheral masses on chest
X-ray were chosen for the study since it was possible to
separate tumour from mediastinal structures on the scans in
these patients. The patients were scanned on a GE 9800
Whole Body Scanner. Scans were performed at 1 cm intervals
throughout the region of the tumour. Where necessary, a
bolus of intravenous contrast medium was administered to
delineate vascular structures. The area of the lesion was then
calculated on each image using a tracing device. As the scan
thickness was I cm in each image the volume could be easily
estimated. Care was taken to avoid measuring areas of lung
consolidation or collapse, although this was not always possi-
ble. Where such discrimination was difficult in a series of
scans a special effort was made to measure the same struc-
tures on each scan in the series. However, the initial
measurements in this series were often made as the scans
became available, several weeks apart.
One patient died during therapy and consequently has only
three tumour volumes recorded; the rest have at least four,
generally five, and in one case seven tumour volumes
measured.
Methods
In order to estimate the model's parameters, i.e. the propor-
tion of sensitive tumour killed with each cycle of therapy, k,
the resistance at presentation Ro, and the tumour doubling
time d, four tumour volumes are required. Hence the model
could only be applied to eight of the nine patients.
With only four volumes, ifthe model fits the observed data
Table I Tumour volumes (cm3) and times (in days since start of
treatment) at which scans were performed
Pre-course
Patient 1 2 3 4 5 6 7
I Volume 15.2 7.65 4.96 3.84 2.41 2.53 1.66
Time 0 23 44 65 86 107 135
2 Volume 46.7 29.7 27.1 23.0 23.2
Time 0 20 50 78 103
3 Volume 231.7 176.8 100.9 111.0
Time 0 25 46 68
4 Volume 84.2 56.3 37.3 30.9
Time 0 24 39 71
S Volume 12.94 4.66 1.43 0.56 0.49
Time 0 28 42 68 88
6 Volume 27.1 13.3 12.4
Time 0 31 55
7 Volume 98.45 4.1 1.0 ? 0.79 0.80
Time 0 24 42 68 94 115
8 Volume 111.7 70.6 24.0 17.5 9.7
Time 0 21 42 63 84
9 Volume 745.0 380.5 197.2 52.6 43.4 120.8
Time 0 27 48 72 91 118
?= scan not done.
at all, it will fit exactly, since all four volumes will be needed to
estimate the parameters (given four tumour volumes, equa-
tion (1) in the Appendix will generate three equalities, just
sufficient to derive values for the three independent
parameters, k, Ro and d). If the model is not a reasonable
representation of the actual diseases processes, it may be
expected that no values of the parameters would be capable
of predicting the observed volumes. For instance, if the
percentage tumour reduction on the first cycle of treatment
was less than that seen on the second cycle (assuming a
similar interval between cycles) the model would be invalid.
With more than four tumour volumes the accuracy of the
model can be evaluated, assuming the model fits at all, as
just explained, since its consistency in predicting the sequen-
tial tumour volumes can be examined. In these cases (six of
the nine patients), all the tumour volumes were used to
estimate the model's parameters. The model can then be
validated by a x2 test comparing the observed tumour
volumes with those expected under the model assumptions.
Supposing k, R. and d were known, some slight differences
would still be expected between the model predictions and
the actual tumour volumes, due to inaccuracies in measure-
ment, i.e. the variations in marking out the area of tumour
or delineating the tumour from other structures, as well as
collapse and consolidation within the tumour. Hence in order
to estimte k, Ro and d, a normal distribution of errors about
these predictions has been assumed, the mathematics of
which is given in the Appendix. The variance of this distribu-
tion will reflect differences between the observed tumour
volumes and the model's predictions, and will thus measure
the accuracy of the model. Furthermore, in the patients with
more than four volumes, since k, R. and d can be estimated
from just four volumes, these estimates can be used to
predict the remaining volumes, providing a further substan-
tive test of the model's validity. A computer program has
been written, in Microsoft FORTRAN 77 for IBM compati-
ble microcomputers, to produce the estimates, and is
available on request. The estimation procedure takes only a
few seconds to run.
Results
Reproducibility ofvolume estimates
To test the reproducibility and accuracy of the CT volume
estimates, four of the nine patients' volumes were
independently re-measured. The pairs of volumes for these
four patients are given in Table II. Considerable variability
was found in these estimates, with the mean error being 17%.
It appeared that in some cases adjacent normal structures
were included in the measurement on one occasion but not
on the other. When exactly the same structures were included
in the measurements, the results were consistent, and the
measurements were in close agreement.
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The estimates of sensitive tumour kill, resistance and tumour
volume doubling time for each of the eight patients are
150
Figure 2 Comparison of observed tumour volumes (continuous
lines) with those predicted by the model (dashed lines) for
patients 1-5.
Table II Pairs of repeated tumour volume measurements
Volumes before course (cm-)
Patient 1 2 3 4 5 6
3 231.70 176.80 100.90 111.00
230.70 143.70 100.80 110.50
7 1.00 0.79 0.80
1.35 0.96 0.61
8 111.70 70.60 24.00 17.50 9.70
93.19 61.01 28.03 24.27 16.04
9 745.00 380.50 197.20 52.60 43.36 120.80
711.67 432.22 176.60 55.20 39.00 166.00
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shown in Table III. A detailed worked example showing how
the estimates were derived for patient 9 is shown in Table
IV. Initially, a guess is made for the values of the parameters
(see Table IV). The model's predictions, based on these
guesses, are then compared with the actual results (by
evaluating the log-likelihood as described in the Appendix).
A new estimate of the four parameters is produced based on
the differences between the predictions and actuals (this
involves using the semi-Newton algurithm described in the
Appendix). This new estimate should be closer to the actuals
(and thus have a greater likelihood). This procedure is
repeated until the predictions come no closer to the actuals
(i.e. the likelihood no longer increases significantly). The
likelihood for each of the volumes, given the final 'best'
parameters, is given in Table IV, along with a comparison of
the predictions with the actual volumes.
In three patients the estimates for tumour volume doubling
time were very long, implying a very slow growth rate. In
such cases, with the tumour growing so slowly, very small
volume changes would need to be detectable in order to
estimate the doubling time over the short time intervals
considered. Inaccuracies in the volumes measurements
themselves, as previously calculated, are at least as great as
these changes, making estimates of the doubling time
unreliable in such cases. The doubling time in these patients
has thus been assumed to be approximately 150 days, based
on the estimates of others for the extremes in doubling time
in SCLC (Brigham et al., 1978; Tubiana & Malaise, 1979;
Pearlman, 1983). This problem does not significantly affect
the estimates for resistance and tumour-kill, which are less
sensitive to small volume differences.
The accuracy of the model's predictions (see Appendix),
measured by standard deviations of errors about the model's
predictions (given as percentages of the tumour volumes), are
also shown in Table III. The mean percentage standard
deviation of these errors in prediction was 6.5%, excluding the patients with only four volumes measured, where the
predictions matched the observed volumes. This percentage
error is within the likely errors resulting from inaccuracies in
the measurements, as described previously, and confirms that
the model provides a good fit to the data. This can be seen in
Figures 2 and 3, which plot the observed volumes against the
predictions. The x2 goodness-of-fit tests supported this
finding.
The tumour volumes for the patients with more than four
volumes were used to investigate the consistency of the
model's predictions, and to see whether the model could be
used in a predictive sense, for instance in deciding when to
change or to abandon a particular treatment. In these
patients, the first four volumes alone were used to estimate
the sensitive tumour-kill, resistance and doubling time. These
estimates were then used to try and predict the later volumes.
These predictions, along with the actual, measured volumes,
are given in Table V. For patient 9, the predicted volumes
for courses 5 and 6, using the first four volumes, bore no
resemblance to the actual volumes. A further prediction of
the course 6 volume, using the first five volumes, was also
made for this patient, and this prediction is included in Table
V. For the other patients the predictions are close to the
actual volumes.
Discussion
This mathematical model has two important potential uses.
First, it may provide an important short-cut to obtaining
information about resistance to and efficacy of chemo-
Table III Estimates of sensitive tumour-kill (k), resistance (RO) and
doubling time (d) for the nine patients
Number Likely
of %
Patient scans Regimea k(%) R0 (%) d (days) errorb
1 7 OVA 46 11 > 150 11
2 5 VP5 66 0.85 23 2
3 4 VPI 92 0.06 8 0
4 4 VP1 49 9 88 0
5 5 VP5 81 0.36 30 7
6 3 VPI ? ? ?
7 5 VA 97 0.84 > 150 4
8 5 OVA 59 2 92 15
9 6 VP5 90 0.01 12 19
aOVA: oncovin, vincristine, adriamycin. VA: vincristine, adriamycin.
VPI: VP16 given over I day. VP5: VP16 given over 5 days. bOne
standard deviation oferrors about model predictions (see Appendix).
? = insufficient scans to apply model.
Table IV A worked example for patient 9, including acomparison of
model predictions with actual volumes
Initial guesses for the parameters were:
k = 0.8, Ro = 0.0005, d= 14 days, s.d. (a) = 0.2, X0 = 745 cm3.
(The initial log-likelihood was -48.263).
The semi-Newton maximisation routine produced the 'best' (or
maximum likelihood) estimates at the following parameter values:
k = 0.90, Ro = 0.0001, d= 11.7 days, s.d. (a) = 0.169, X0 = 793 cm3.
(The maximum log-likelihood was 2.163).
The actual values and predictions were as follows
Coursea Time Actuals Predictions Likelihood
(i) (days) Xi Log (X,J u Log (u) L Log (L)
0 0 745.00 6.61 793.07 6.68 2.21 0.79
1 27 380.50 5.94 400.91 5.99 2.25 0.81
2 48 197.25 5.28 143.62 4.97 0.40 -0.91
3 72 52.60 3.96 67.36 4.21 0.81 -0.21
4 91 43.60 3.78 41.54 3.73 2.27 0.82
5 118 120.80 4.79 121.21 4.80 2.36 0.86
aCourse 0 is the pre-treatment value.
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Figure 3 Comparison of observed tumour volumes (continuous lines) with those predicted by the model (dashed lines) for
patients 6-9.
Table V Model predictions of later tumour volumes from earlier
tumour volumes
Number of Course
volumes used ActualsC Patient inprediction predictions 5 6 7
1 4 actuals 2.41 2.53 1.66
predictions 2.50 2.11 1.88
2
5
7
8
9
9
4
4
4
4
4
5
actuals 23.2
predictions 17.6
actuals 0.49
predictions 0.26
actual
predictions
0.80
0.83
actual 9.7
predictions 11.3
actual 43.4 120.8
predictions 23.0 11.0
actual
predictions
120.8
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therapy. At present such information is only obtained from
randomised trials addressing these questions, and then only
by interpretation from the gross outcome measures of res-
ponse duration and survival. The method described in this
report enables these factors to be estimated for individual
patients, and thus the effects of the treatments can be more
easily evaluated. The patient numbers in the studies reported
were insufficient to enable general conclusions to be drawn
about differences in tumour kill and resistance between the
different treatments. This information should, however, be
obtainable from relatively small trials, depending on the
magnitude of any differences.
The second use of this model is in predicting when to alter
or stop treatment. Predictions of later volumes using earlier
ones were fairly accurate, as shown by Table V. For patient
9, there was a clear alteration in the pattern of continued
tumour reduction at the fifth volume. The reduction at this
volume did not match the large reductions seen with earlier
volumes. (Using the first four volumes, the fifth was
predicted to be only 23 cm3, compared with the observed
value of 43 cm3 - see Table V.) The model detected that this
lessening of the tumour-kill presaged rapid re-growth. This
would have been the moment to stop treatment, or switch to
a possibly non-cross-resistant alternative.
Alternative models (e.g. Birkhead et al., 1987) can be
considered where a proportion of the tumour is non-dividing,
due, for example, to lack of vascularisation. However, this
assumption was considered unnecessary, and was thought to
add needless complexity in SCLC. In this tumour the mono-
clonal antibody Ki67, which stains cells not in the GO phase
of the cell cycle, suggests that 60% or more of the cells are in
cycle at any one time (Gatter et al., 1986).
The reproducibility of the tumour volumes, especially
where identical structures can be measured on each occasion,
appears in this study to be good, and certainly sufficient to
enable estimation of the model parameters. The model
appears to predict the data fairly accurately, with the average
standard deviation of errors in volume being approximately
9%.
It is interesting to note that, with the exception of patient
7, there appears to be a relationship between k, the tumour-
kill, and d, the doubling time (r = - 0.89, P = 0.004). This
seems intuitively reasonable, with therapy being more
effective on rapidly dividing tumours. It may be that the
course 5 and 6 volumes for patient 7 represent non-dividing
cells, as described.
It is likely that the doubling time of a tumour reflects a
balance between the rate at which the cells are proliferating
and the rate of cell loss. This would not significantly affect
the model's estimates or validity, since it makes assumptions
only about the gross tumour volume. It may, however, help
to reconcile the relatively slow doubling time estimated by
the model with the large proportion of dividing cells found
with the monoclonal antibody Ki67, and with the relatively
high cell-kills estimated and presented in Table III.
It is interesting that a wide variability in proportions of
initially resistant tumour was seen, as suggested by Goldie &
Coldman (1982), using a model where resistance is acquired
by spontaneous mutation.
Cancers other than SCLC, with tumour markers, may
provide better applications for this model. However, since
SCLC is a highly chemosensitive tumour, alterations in dose
and schedule provide hope of significant, and sorely needed,
improvements. In another application, this model helped to
explain why high-dose cyclophosphamide failed to cure more
patients with SCLC (Gregory et al., 1988). Such explanations
may aid in the design of new and better protocols.
Appendix
The model predicts that sequential tumour volumes before
treatment (A0, XI, X2, ...,X.,) will bedescribed by theequation:
XiI-a-(I-a
)koXoei (i = 1, 2, n) (1)
where a = (1-k), ko= k(l -RO), k is the proportion of the
sensitive tumour killed with each course of therapy, Ro is the
proportion of the tumour initially resistant, a is the (exponen-
tial) growth rate, t, is the time between first treatment and
treatment cycle i + 1, and i is the treatment cycle number itself.
From equation (1)
log Xi= log [ ja) (I I) + log XO + ati (2)
Let the actual tumour volumes tumours be VO, VI, ..., Vn.
Since the tumour is growing exponentially, and large errors are
more likely when measuring large tumours, it will be assumed
that errors in measurement of these volumes are log-normally
distributed about the model's predictions (equation 2) with
some constant standard deviation a (this is equivalent to the
assumption that the same percentage error can be expected at
each tumour volume).
Then the likelihood of the (log of) the volumes under the
model, L, is
L(log VO, log V, log V.) = N(log VO, log XO, oa). N(log V,, log XI, x) ... N(log V., log Xn, ax)
n
=7T N(log Vi, log Xi, (x)
i=O
whereN(x, u, a)isthevalueofanormaldistribution withmean u
and variance a at x.
Hence
n
log L = E log N(log VJ, log Xi, ax)
i=O
a11 P [ 2(U2 1
Now N(x, u, a) =V2rexp 2a J
So log L =
_ log [c,27i exp [( 2l ) 11(3)
The maximum likelihood estimates (MLRs) for XO, k, J0, a
and a (i.e. the values of these parameters which produce the
closest fit between the model's predictions and the data) can
then be obtained by maximising log L from (3). This can be
achieved by differentiating log L with respect to each of the
parameters XO, k, Ro, aand a andmaximising logLbased on the
values of these derivatives using a semi-Newton algorithm. It
would be tedious to give all the derivatives in full; that for k, as
an example, is
alogL ko(logA-log Vi) ko i a'-'
ak i=O a [I-a-(I-d)ko]
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